Published in Cancer on September 01, 2001
Integrins: roles in cancer development and as treatment targets. Br J Cancer (2004) 2.76
The minimum element of a synthetic peptide required to block prostate tumor cell migration. Cancer Biol Ther (2006) 2.20
Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging (2006) 1.39
Integrin targeted therapeutics. Theranostics (2011) 1.36
Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs (2007) 1.18
Integrin alpha(v)beta(3)-Targeted Cancer Therapy. Drug Dev Res (2008) 1.17
Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer (2004) 1.15
Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia (2004) 1.00
Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner. Clin Exp Metastasis (2007) 0.90
Miniaturized pre-clinical cancer models as research and diagnostic tools. Adv Drug Deliv Rev (2013) 0.89
Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study. Invest New Drugs (2006) 0.89
Controlled breast cancer microarrays for the deconvolution of cellular multilayering and density effects upon drug responses. PLoS One (2012) 0.85
Production and characterization of a humanized single-chain antibody against human integrin alphav beta3 protein. J Biol Chem (2011) 0.82
Recent translational research: antiangiogenic therapy for breast cancer - where do we stand? Breast Cancer Res (2004) 0.80
Differential regulation of monocyte cytokine release by αV and β(2) integrins that bind CD23. Immunology (2012) 0.76
Small molecular peptide-ScFv αvβ3 conjugates specifically inhibit lung cancer cell growth in vitro and in vivo. Am J Cancer Res (2016) 0.75
Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet (1995) 4.01
Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum Reprod (2010) 2.65
Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol (2004) 2.63
Extraskeletal osteosarcoma. A clinicopathologic review of 26 cases. Cancer (1990) 2.56
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol (1997) 2.32
X-ray diffraction analysis of matrix porin, an integral membrane protein from Escherichia coli outer membranes. J Mol Biol (1983) 2.29
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med (1997) 2.22
A brief method for assessing expressed emotion in relatives of psychiatric patients. Psychiatry Res (1986) 2.19
Kepler's optical phase curve of the exoplanet HAT-P-7b. Science (2009) 2.18
Sequence of an HLA-DR alpha-chain cDNA clone and intron-exon organization of the corresponding gene. Nature (1982) 2.18
Sequence and analysis of chromosome 3 of the plant Arabidopsis thaliana. Nature (2000) 2.17
Revised FDA labeling guideline for theophylline oral dosage forms. Pharmacotherapy (1995) 2.11
Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer (1974) 2.10
Information Technology for postgraduate education: survey of facilities and skills in the South West Deanery. Br J Obstet Gynaecol (1999) 2.04
Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. Ann Intern Med (1989) 2.03
Objective birth data and the prediction of child abuse. Arch Dis Child (1981) 1.91
Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer (2001) 1.89
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med (1982) 1.85
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer (1976) 1.85
Sequence and analysis of chromosome 1 of the plant Arabidopsis thaliana. Nature (2000) 1.85
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol (2012) 1.81
Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res (1987) 1.74
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer (1995) 1.65
Changing clinical picture of non-accidental injury to children. Br Med J (Clin Res Ed) (1983) 1.60
Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg (1990) 1.59
The structure of Bacillus subtilis pectate lyase in complex with calcium. Nat Struct Biol (1994) 1.53
Soft tissue sarcomas of the head and neck in adolescents and adults. Am J Surg (1986) 1.50
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin. N Engl J Med (1974) 1.48
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol (2001) 1.47
Genomic medicine: who will practice it? A call to open arms. Am J Med Genet (2001) 1.47
Adriamycin cardiomyopathy--risk factors. Cancer (1977) 1.46
Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol (1998) 1.45
Metastatic patterns of choroidal melanoma. Cancer (1974) 1.45
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep (1976) 1.45
Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol (1999) 1.45
Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet (2005) 1.44
Factors related to length of complete remission in adult acute leukemia. Cancer (1980) 1.42
Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol (2010) 1.42
Towards a clinically useful classification of OHSS. Reprod Biomed Online (2009) 1.41
The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology (1985) 1.41
Ovarian hyperstimulation syndrome: an endocrinopathy? Curr Opin Obstet Gynecol (2001) 1.40
Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst (1991) 1.40
Observation of B(0)(s)-->Psi(2S)Phi and measurement of the ratio of branching fractions Beta(B(0)(s)-->Psi(2S)Phi)/Beta(B(0)(s)-->J/PsiPhi). Phys Rev Lett (2006) 1.40
The effect of norepinephrine versus epinephrine on myocardial hemodynamics during CPR. Ann Emerg Med (1989) 1.39
Hib disease must be prevented. Med J Aust (1994) 1.39
Hepatitis A epidemiology in Australia: national seroprevalence and notifications. Med J Aust (2001) 1.38
Combination chemotherapy in adult desmoid tumors. Cancer (1993) 1.36
Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res (1977) 1.36
Two crystal structures of pectin lyase A from Aspergillus reveal a pH driven conformational change and striking divergence in the substrate-binding clefts of pectin and pectate lyases. Structure (1997) 1.35
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol (1997) 1.34
IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood (1998) 1.33
Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol (1998) 1.32
Beta-lactam antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients. Am J Med Sci (1976) 1.32
Structural analysis of the 2.8 A model of Xylose isomerase from Actinoplanes missouriensis. Proteins (1988) 1.31
Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up. Cancer (1999) 1.31
Crystal structure of polygalacturonase from Erwinia carotovora ssp. carotovora. J Biol Chem (1998) 1.30
Precision top-quark mass measurement at CDF. Phys Rev Lett (2012) 1.30
Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol (1998) 1.29
Role of radiotherapy in sarcoma of the breast--a retrospective review of the M.D. Anderson experience. Radiother Oncol (1999) 1.29
Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies. Antimicrob Agents Chemother (1972) 1.28
A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol (1984) 1.28
Sarcoma of the breast: implications for extent of therapy. The M. D. Anderson experience. Surgery (1994) 1.28
Chemoimmunotherapy of adult acute leukaemia. Prolongation of remission in myeloblastic leukaemia with B.C.G. Lancet (1974) 1.27
A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol (1983) 1.27
A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer (1989) 1.27
Doxorubicin-induced congestive heart failure in adults. Cancer (1985) 1.26
Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol (1999) 1.25
Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer (1993) 1.25
Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res (1974) 1.25
Transactivation of the p53 oncogene by E1a gene products. Virology (1990) 1.25
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Pleomorphic xanthoastrocytoma: favorable outcome after complete surgical resection. Neuro Oncol (2001) 1.22
Measurement of the cross section for prompt isolated diphoton production using the full CDF run II data sample. Phys Rev Lett (2013) 1.22
Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int (2009) 1.22
Arginine residues as stabilizing elements in proteins. Biochemistry (1992) 1.21
Chemotherapy for metastatic carcinoid tumors: experiences with 32 patients and a review of the literature. Cancer Treat Rep (1977) 1.21
Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA (1988) 1.20
Homoeopathic vaccination. What does it mean? Immunisation Interest Group of the Royal Alexandra Hospital for Children. Med J Aust (1994) 1.20
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol (1995) 1.20
Outcome of maple syrup urine disease. Arch Dis Child (1982) 1.20
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19